Affiliation: Armed Forces Research Institute of Medical Sciences
- Enhanced sensitivity of detection of cytotoxic T lymphocyte responses to HIV type 1 proteins using an extended in vitro stimulation period for measuring effector function in volunteers enrolled in an ALVAC-HIV phase I/II prime boost vaccine trial in ThailWannee Kantakamalakul
Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
AIDS Res Hum Retroviruses 20:642-4. 2004..These results imply that extension of the IVS period may increase the sensitivity of the CRA when measuring HIV-specific CTL in ALVAC-HIV prime-boost recipients without compromising specificity...
- Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in ThailandChitraporn Karnasuta
Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
Vaccine 23:2522-9. 2005..The results demonstrate that this HIV vaccine is a potent inducer of ADCC activity and may be an additional protection of this prime-boost vaccine in preventing HIV disease...
- A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boostPrasert Thongcharoen
Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand
J Acquir Immune Defic Syndr 46:48-55. 2007..A prime-boost HIV-1 vaccine trial assessing safety and immunogenicity was conducted in Thailand as part of an evaluation of candidate regimens for a phase 3 efficacy trial...
- Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adultsSorachai Nitayaphan
Royal Thai Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
J Infect Dis 190:702-6. 2004..This vaccine combination was well tolerated and was immunogenic, meeting milestones for advancement to phase 3 evaluation...
- HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/ERobert Paris
Department of Retrovirology and Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
Vaccine 30:832-6. 2012..009). These data suggest that the lack of response to a vaccine designed to induce clade-specific NAb to HIV-1 is associated with the presence of certain HLA class II alleles and heterodimers in some Southeast Asians...
- Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy UgandansMichael A Eller
Makerere University Walter Reed Project, Kampala, Uganda
Vaccine 25:7737-42. 2007....